Abstract:You have accessJournal of UrologyBladder Cancer: Basic Research & Pathophysiology I (MP15)1 May 2024MP15-11 CD103+CD8+ TISSUE-RESIDENT MEMORY T CELLS INFILTRATION PREDICTS CLINICAL OUTCOME AND ADJUVANT THERAPEUTIC BENEFIT IN MUSCLE-INVASIVE BLADDER CANCER Kaifeng Jin, Zhaopei Liu, Zewei Wang, and Jiejie Xu Kaifeng JinKaifeng Jin , Zhaopei LiuZhaopei Liu , Zewei WangZewei Wang , and Jiejie XuJiejie Xu View All Author Informationhttps://doi.org/10.1097/01.JU.0001009500.87761.bf.11AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: CD103+CD8+ tissue-resident memory T (TRM) cells, associated with better overall survival among various malignancies, are thought to activate anti-tumor immune response and affect therapeutic sensitivity including both immunotherapy and adjuvant chemotherapy (ACT). METHODS: Totally 650 muscle-invasive bladder cancer (MIBC) patients from three independent cohorts were included in this study for survival and cisplatin-based ACT response analysis. Another public dataset consisting of 195 patients from IMvigor210 trial receiving PD-L1 blockade were involved in the assessment of immunotherapeutic response. Fifty-nine fresh tumor tissues were used to evaluate immune infiltration of CD103+CD8+ TRM cells. RESULTS: Patients with high CD103+CD8+ TRM cells infiltration, but not CD8+ T cells, are more likely to benefit from immunotherapy and ACT. The presence of TRM cells is highly associated with an enhanced IFNγ-enriched and T cell-inflamed anti-tumor microenvironment. Elevated CD103+CD8+ TRM cells infiltration correlated with superior ACT response in mismatch repair (MMR), homologous recombination (HR), PIK3CA/AKT and RAS/RAF pathway proficient or histone modification and cell cycle pathway deficient patients. CONCLUSIONS: CD103+CD8+ TRM cells played a crucial role in anti-tumor immunity and served as an ideal prognostic biomarker. It could be treated as a superior companion predictor for treatment response to PD-L1 inhibitor and ACT within MIBC patients. Download PPT Source of Funding: This study was funded by grants from National Natural Science Foundation of China (31770851, 81872082, 82002670, 82103408), Shanghai Municipal Natural Science Foundation (19ZR1431800), Shanghai Sailing Program (18YF1404500, 21YF1407000), Shanghai Municipal Commission of Health and Family Planning Program (201840168) and Fudan University Shanghai Cancer Center for Outstanding Youth Scholars Foundation (YJYQ201802). All these study sponsors have no roles in the study design, in the collection, analysis and interpretation of data © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e233 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Kaifeng Jin More articles by this author Zhaopei Liu More articles by this author Zewei Wang More articles by this author Jiejie Xu More articles by this author Expand All Advertisement PDF downloadLoading ...

CD103+CD8+ tissue-resident memory T cell infiltration predicts clinical outcome and adjuvant therapeutic benefit in muscle-invasive bladder cancer

MP15-11 CD103 + CD8 + TISSUE-RESIDENT MEMORY T CELLS INFILTRATION PREDICTS CLINICAL OUTCOME AND ADJUVANT THERAPEUTIC BENEFIT IN MUSCLE-INVASIVE BLADDER CANCER

CD103+ Tissue-Resident CD8+ T Cells Correlate with Protective Anti-Tumoral Immune Responses in Muscle-Invasive Bladder Cancer Patients.

Identification of a Cisplatin Resistant-Based Prognostic Immune Related Gene Signature in MIBC

Intratumoral TIGIT + CD8 + T-cell infiltration determines poor prognosis and immune evasion in patients with muscle-invasive bladder cancer

TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer

Identification and Validation of an Excellent Prognosis Subtype of Muscle-Invasive Bladder Cancer Patients with Intratumoral CXCR5+ CD8+ T Cell Abundance.

CD19(+) Tumor-Infiltrating B-cells Prime CD4(+) T-cell Immunity and Predict Platinum-Based Chemotherapy Efficacy in Muscle-Invasive Bladder Cancer

Intratumoral CCR5+ neutrophils identify immunogenic subtype muscle-invasive bladder cancer with favorable prognosis and therapeutic responses

Intratumoral CXCL13+CD8+T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma

Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer

Intratumoral IL22-producing Cells Define Immunoevasive Subtype Muscle-Invasive Bladder Cancer with Poor Prognosis and Superior Nivolumab Responses

Tumor Stroma-Infiltrating Mast Cells Predict Prognosis and Adjuvant Chemotherapeutic Benefits in Patients with Muscle Invasive Bladder Cancer.

Tumor-infiltrating IL-17A+ Cells Determine Favorable Prognosis and Adjuvant Chemotherapeutic Response in Muscle-Invasive Bladder Cancer

Tissue-resident memory CD103+CD8+ T cells in colorectal cancer: its implication as a prognostic and predictive liver metastasis biomarker

Mp55-02 ccr8 blockade primes anti-tumor immunity through intratumoral regulatory t cells destabilization in muscle-invasive bladder cancer

Limited Predictive or Prognostic Role of Tumor-Infiltrating Tissue-Resident Memory CD8 T Cells in Patients with Hepatocellular Carcinoma Receiving Immunotherapy

Stromal LAG-3+cells Infiltration Defines Poor Prognosis Subtype Muscle-Invasive Bladder Cancer with Immunoevasive Contexture

Stromal Tumor-Associated Macrophage Infiltration Predicts Poor Clinical Outcomes in Muscle-Invasive Bladder Cancer Patients

Intratumoral CD103+ CD8+ T Cells Predict Response to PD-L1 Blockade

Integrating molecular subtype and CD8+ T cells infiltration to predict treatment response and survival in muscle-invasive bladder cancer